Ludwig Enterprises

What Ludwig Enterprises does

Ludwig Enterprises, Inc. is a clinical-stage health technology company headquartered in Pompano Beach, Florida, operating under the Revealia™ brand. The company markets an at-home cancer screening product that uses a 2-minute cheek swab to collect samples, which are then analyzed at a CAP/CLIA-certified contracted laboratory (Grace Health Technology) using a platform combining 48 mRNA genetic biomarkers, nanoscale detection technology, and AI-based analysis. The flagship commercial SKU is the Revealia™ Breast Cancer Home Screening Kit, advertised with 97% sensitivity (product page) / 92% (homepage), room-temperature storage, and a prepaid return envelope. The company has collected 3,600+ patient samples across 40 US clinics under an IRB-approved clinical protocol and is currently conducting PCR validation testing of its screening platform. Ludwig has filed a provisional patent on its cancer screening algorithm and acquired additional cancer-screening IP, and holds the registered Revealia™ trademark.

The business operates on a direct-to-consumer e-commerce model through ludwigent.com, with kits shipped to U.S. addresses only and a state-by-state waitlist gating availability. Pricing is not publicly disclosed; customers are routed to a contact email or phone number. The company has not disclosed commercial revenue, and a single small working-capital event is recorded: a $250,000 convertible promissory note issued to Alumni Capital LP in February 2026, accompanied by warrants for 4,166,667 shares at $0.06. In March 2026 Ludwig completed a share-exchange agreement with Exousia Pro, eliminating 47 million shares of potential dilution. Distribution is single-channel (own website), marketing is concentrated in PR, website, email newsletter, and a shareholder ambassador program, and the patient population is primarily health-conscious adult consumers seeking non-invasive, at-home screening. The company is described in third-party sources as OTC-traded with no formal exchange listing; firmographics list 101–250 employees.

Name

Ludwig Enterprises

Legal name

Ludwig Enterprises, Inc.

Website

https://ludwigent.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

101–250 employees

Short description

Ludwig Enterprises is a clinical-stage health technology company operating the Revealia™ brand, selling an at-home, AI-powered multi-cancer screening kit that analyzes 48 mRNA biomarkers from a cheek swab via a CAP/CLIA-certified lab for U.S. health-conscious consumers.

Ownership category

akta.pro rank

Product category

Cancer Screening Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Home Diagnostic & Self-Test OTC Kits (HLAIADAO)

Keywords

• At-home cancer screening
• MRNA biomarker testing
• Multi-cancer early detection
• Non-invasive diagnostics
• Genetic health screening

Headquarters

HQ city

Pompano Beach

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. At-home Cancer Screening Kits: Direct-to-consumer sales of Revealia breast cancer home screening kits. Customers purchase kits online, perform cheek swab tests at home, mail samples to CAP/CLIA certified lab, and receive results digitally. Kit includes 2 cheek swabs, instruction booklet, and prepaid return envelope.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Ludwig Enterprises develops and sells Revealia™, an at-home multi-cancer early screening kit. Customers order kits online, perform a 2-minute painless cheek swab at home, mail samples to CAP/CLIA-certified laboratories, and receive digital results. The product uses 48 mRNA genetic biomarkers, nanoscale detection, and AI-powered analysis to screen for inflammatory biomarkers associated with cancer and other diseases.

Product overview

Ludwig Enterprises offers a single unified product line centered on Revealia™, an AI-powered multi-cancer early screening platform. The flagship Revealia™ test uses a non-invasive cheek swab to collect samples which are analyzed at CAP/CLIA-certified laboratories using 48 mRNA genetic biomarkers and nanoscale detection technology combined with artificial intelligence. Results are delivered digitally within 2 minutes. The company also markets a specific Breast Cancer Home Screening Kit variant with 97% sensitivity, positioning it as the world's most convenient cancer screening solution with at-home convenience, room temperature storage, and prepaid return shipping. Both products share the same core technology stack and laboratory infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

• Revealia: At-home cancer screening test using cheek swab technology and AI analysis of 48 mRNA biomarkers for early detection of cancer and inflammatory conditions.

Products and services

• Revealia™ Multi-Cancer Early Screening Kit AI-powered at-home multi-cancer early screening kit that analyzes 48 mRNA biomarkers from a 2-minute cheek swab using nanoscale detection and AI, delivering digital results to individual consumers. Screens for inflammatory biomarkers associated with cancer and other diseases.
• Revealia™ Breast Cancer Home Screening Kit At-home breast cancer screening kit with 97% sensitivity, using a painless cheek swab, room temperature storage, prepaid return envelope, and digital result delivery, analyzed at CAP/CLIA-certified laboratories.

Quantifiable outcome

• 97% sensitivity rate in breast cancer screening
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

One partnership is on record.

• Grace Health TechnologycoreTechnology or IntegrationContracted laboratory partner mentioned in privacy policy. Grace Health Technology performs screening analysis and shares results with Ludwig Enterprises under strict confidentiality. The lab is CAP and CLIA certified.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• GRAIL: Developer of the Galleri multi-cancer early detection blood test; the most directly analogous multi-cancer early screening platform pursuing the same early-detection customer use case with a different sample matrix (blood vs. cheek swab).
• Natera: Provides cell-free DNA-based oncology tests (Signatera for MRD, Empower for hereditary cancer screening); competes for the same screening-adjacent oncology consumer with next-generation molecular testing.
• Freenome: Multi-cancer early detection company developing blood-based screening using methylated cell-free DNA and multi-analyte biology; a frontier direct competitor using AI/multi-omics — a near-perfect technology analog.
• Guardant Health: Liquid biopsy oncology company offering blood-based screening and recurrence monitoring (Guardant Reveal, Shield) — overlaps directly in early cancer detection through novel biomarker analytics.
• Exact Sciences: Markets Cologuard, the leading direct-to-consumer/at-home colorectal cancer screening test, plus Oncotype DX and the acquired Thrive Earlier Detection business — the closest commercial analog in DTC cancer screening with established payor coverage.
• Thrive Earlier Detection: Multi-cancer blood test developer acquired by Exact Sciences; pioneered the multi-cancer early detection (MCED) concept with the PATHFINDER study, making it a definitional peer to Ludwig's MCED positioning.

Broad incumbents

• Quest Diagnostics: Large incumbent clinical laboratory and diagnostic testing services provider with broad oncology and consumer-initiated testing offerings; overlaps as a broad diagnostics infrastructure and competitor for screening lab services.

Emerging players

• Adela: Epigenomic-based cancer detection developer using methylated DNA signatures for early multi-cancer detection from blood; an emerging-stage player in the same MCED category with adjacent biomarker architecture.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ludwig Enterprises